CytoDyn Inc. (CYDY) Plans to File IND for Clinical
Post# of 154118
(Total Views: 375)
Posted On: 08/21/2018 7:21:01 PM
CytoDyn Inc. (CYDY) Plans to File IND for Clinical Trial of PRO 140 in Colon Carcinoma Patients following Significant Preclinical Results
- PRO 140 has been shown effective in inhibiting the growth of a human colon carcinoma cell line (SW480) in a prominent mouse model
- PRO 140 extended the lives of treated mice and reduced tumor growth by more than 50 percent
- CytoDyn was recently featured favorably in a report by a leading independent small cap media portal
Biotechnology company CytoDyn Inc. (OTCQB: CYDY) recently announced exciting progress (http://nnw.fm/Md2hq) in the development of PRO 140 (leronlimab), its novel humanized CCR5 monoclonal antibody, which has multiple therapeutic indications including treating HIV, cancer and inflammatory conditions.
In preclinical studies conducted over the past year, PRO 140 was shown effective in inhibiting the growth of a human colon carcinoma cell line (SW480) in a prominent mouse model. The statistically significant results will provide a basis for the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for a clinical trial of PRO 140 in colon carcinoma patients, which CytoDyn plans to file within the next few weeks.
In the studies, two different strains of immuno-incompetent mice were used to grow SW480 human tumor cells, with different doses of PRO 140 being used as part of the studies. The SW480 cell line was derived from a patient with colon adenocarcinoma; like many human cancers, the cell line was CCR5-positive.
In comparison with the control mice, the lives of the mice treated with PRO 140 were extended, and tumor growth decreased by more than 50 percent, which was statistically significant. The results were dose-dependent and were repeated in separate experiments. Preclinical studies that are currently ongoing are defining the mechanisms involved in PRO 140’s anti-tumor efficacy.
CytoDyn believes that CCR5 is a crucial receptor in the growth and invasiveness of human malignancies, and that premise is supported by these studies. In addition to CytoDyn’s recent announcement regarding PRO 140’s potential in metastatic breast cancers (http://nnw.fm/h7OMm), the company believes that these results in colon cancer further support that, if approved, PRO 140 may offer patients with breast and colon cancers an important potential therapeutic option.
In addition to filing an IND to commence studies of PRO 140 for treating colon carcinoma, CytoDyn will continue exploring the biological pathways involving CCR5 to identify other potential therapeutic applications for PRO 140.
In other news from CytoDyn, a favorable report about the company was recently published (http://nnw.fm/niIC3) by leading independent small cap media portal EmergingGrowth.com. The report detailed the disruptive potential of PRO 140 in targeting HIV, along with its other potential clinical applications, and also discussed CytoDyn’s market valuation and current undervalued status.
In further company news, CytoDyn has noted that, upon the closing of its proposed acquisition of ProstaGene, Richard G. Pestell, Ph.D, M.D., is expected to be appointed as CytoDyn’s chief medical officer. Pestell is currently serving as the CEO of ProstaGene and as president of the Pennsylvania Cancer and Regenerative Medicine Research Center.
CytoDyn has also appointed Michael A. Klump, president and CEO of Argonne Capital Group, to its board of directors, as noted in a recent press release (http://nnw.fm/Ay2Q5).
For more information, visit the company’s website at www.CytoDyn.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- PRO 140 has been shown effective in inhibiting the growth of a human colon carcinoma cell line (SW480) in a prominent mouse model
- PRO 140 extended the lives of treated mice and reduced tumor growth by more than 50 percent
- CytoDyn was recently featured favorably in a report by a leading independent small cap media portal
Biotechnology company CytoDyn Inc. (OTCQB: CYDY) recently announced exciting progress (http://nnw.fm/Md2hq) in the development of PRO 140 (leronlimab), its novel humanized CCR5 monoclonal antibody, which has multiple therapeutic indications including treating HIV, cancer and inflammatory conditions.
In preclinical studies conducted over the past year, PRO 140 was shown effective in inhibiting the growth of a human colon carcinoma cell line (SW480) in a prominent mouse model. The statistically significant results will provide a basis for the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for a clinical trial of PRO 140 in colon carcinoma patients, which CytoDyn plans to file within the next few weeks.
In the studies, two different strains of immuno-incompetent mice were used to grow SW480 human tumor cells, with different doses of PRO 140 being used as part of the studies. The SW480 cell line was derived from a patient with colon adenocarcinoma; like many human cancers, the cell line was CCR5-positive.
In comparison with the control mice, the lives of the mice treated with PRO 140 were extended, and tumor growth decreased by more than 50 percent, which was statistically significant. The results were dose-dependent and were repeated in separate experiments. Preclinical studies that are currently ongoing are defining the mechanisms involved in PRO 140’s anti-tumor efficacy.
CytoDyn believes that CCR5 is a crucial receptor in the growth and invasiveness of human malignancies, and that premise is supported by these studies. In addition to CytoDyn’s recent announcement regarding PRO 140’s potential in metastatic breast cancers (http://nnw.fm/h7OMm), the company believes that these results in colon cancer further support that, if approved, PRO 140 may offer patients with breast and colon cancers an important potential therapeutic option.
In addition to filing an IND to commence studies of PRO 140 for treating colon carcinoma, CytoDyn will continue exploring the biological pathways involving CCR5 to identify other potential therapeutic applications for PRO 140.
In other news from CytoDyn, a favorable report about the company was recently published (http://nnw.fm/niIC3) by leading independent small cap media portal EmergingGrowth.com. The report detailed the disruptive potential of PRO 140 in targeting HIV, along with its other potential clinical applications, and also discussed CytoDyn’s market valuation and current undervalued status.
In further company news, CytoDyn has noted that, upon the closing of its proposed acquisition of ProstaGene, Richard G. Pestell, Ph.D, M.D., is expected to be appointed as CytoDyn’s chief medical officer. Pestell is currently serving as the CEO of ProstaGene and as president of the Pennsylvania Cancer and Regenerative Medicine Research Center.
CytoDyn has also appointed Michael A. Klump, president and CEO of Argonne Capital Group, to its board of directors, as noted in a recent press release (http://nnw.fm/Ay2Q5).
For more information, visit the company’s website at www.CytoDyn.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)